WO2009069682A1 - 肝炎の治療剤又は予防剤 - Google Patents

肝炎の治療剤又は予防剤 Download PDF

Info

Publication number
WO2009069682A1
WO2009069682A1 PCT/JP2008/071508 JP2008071508W WO2009069682A1 WO 2009069682 A1 WO2009069682 A1 WO 2009069682A1 JP 2008071508 W JP2008071508 W JP 2008071508W WO 2009069682 A1 WO2009069682 A1 WO 2009069682A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleotides
length
hepatitis
agent
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/071508
Other languages
English (en)
French (fr)
Inventor
Tomokatsu Iwamura
Akiko Soneda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Priority to JP2009543838A priority Critical patent/JP5359883B2/ja
Publication of WO2009069682A1 publication Critical patent/WO2009069682A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本発明は、インターフェロン（ＩＦＮ）誘導活性が増強され、かつ炎症性サイトカイン誘導活性が低減された新規な免疫刺激オリゴヌクレオチドと、インターフェロン－βとの併用による、肝炎の治療剤又は予防剤を提供することを目的とする。本発明は、式（１）：５’－（Ｇ）ＭＰＸＣＧＹＱ（Ｇ）Ｎ－３’[式（１）中、Ｃは、シトシン、Ｇは、グアニン、Ｘ及びＹは、それぞれ独立に、４塩基以上連続したグアニンを含まない０～１０ヌクレオチド長の塩基配列（但し、Ｘ＋Ｙの長さは、６～２０ヌクレオチド長である。）、ＸＣＧＹは、少なくとも８ヌクレオチド長のパリンドローム配列を含む８～２２ヌクレオチド長の塩基配列、Ｐ及びＱは、それぞれ独立に、グアニン以外の１ヌクレオチド、Ｍは、６～１０の整数、Ｎは、０～３の整数を表す。]で示され、全長が１６～３７ヌクレオチド長であるオリゴヌクレオチド（但し、配列表の配列番号５記載の塩基配列からなるものは除く。）と、インターフェロン－βと、を有効成分とする、肝炎の治療剤又は予防剤を提供する。
PCT/JP2008/071508 2007-11-28 2008-11-27 肝炎の治療剤又は予防剤 Ceased WO2009069682A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009543838A JP5359883B2 (ja) 2007-11-28 2008-11-27 肝炎の治療剤又は予防剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007307930 2007-11-28
JP2007-307930 2007-11-28

Publications (1)

Publication Number Publication Date
WO2009069682A1 true WO2009069682A1 (ja) 2009-06-04

Family

ID=40678574

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/071508 Ceased WO2009069682A1 (ja) 2007-11-28 2008-11-27 肝炎の治療剤又は予防剤

Country Status (2)

Country Link
JP (1) JP5359883B2 (ja)
WO (1) WO2009069682A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11578331B2 (en) 2015-09-09 2023-02-14 Gilead Sciences, Inc. Combination comprising immunostimulatory oligonucleotides
US11583581B2 (en) 2015-09-21 2023-02-21 Gilead Sciences, Inc. Methods of treating a retroviral infection

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005083076A1 (ja) * 2004-02-27 2005-09-09 Emori & Co., Ltd. インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
JP2005532067A (ja) * 2002-07-03 2005-10-27 コーリー ファーマシューティカル グループ，インコーポレイテッド 刺激性免疫応答用の核酸組成物
JP2005533035A (ja) * 2002-06-03 2005-11-04 アプライド リサーチ システムズ アルス ホールディング ナムローゼ フエンノートシャップ インターフェロン−β皮下投与によるアジア人集団のＣ型肝炎治療
WO2006035939A1 (ja) * 2004-09-30 2006-04-06 Osaka University 免疫刺激オリゴヌクレオチドおよびその医薬用途
WO2006108358A1 (en) * 2005-04-13 2006-10-19 Changchun Huapu Biotechnology Co., Ltd. ANTIVIRAL USE OF ARTIFICIAL CpG-CONTAINING SINGLE-STRANDED OLIGODEOXYNUCLEOTIDES IN COMBINATION WITH RIBAVIRIN
JP2007528848A (ja) * 2003-07-09 2007-10-18 ヴァックスデザイン・コーポレーション ワクチン接種ノードを用いるプログラムされた免疫応答

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533035A (ja) * 2002-06-03 2005-11-04 アプライド リサーチ システムズ アルス ホールディング ナムローゼ フエンノートシャップ インターフェロン−β皮下投与によるアジア人集団のＣ型肝炎治療
JP2005532067A (ja) * 2002-07-03 2005-10-27 コーリー ファーマシューティカル グループ，インコーポレイテッド 刺激性免疫応答用の核酸組成物
JP2007528848A (ja) * 2003-07-09 2007-10-18 ヴァックスデザイン・コーポレーション ワクチン接種ノードを用いるプログラムされた免疫応答
WO2005083076A1 (ja) * 2004-02-27 2005-09-09 Emori & Co., Ltd. インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
WO2006035939A1 (ja) * 2004-09-30 2006-04-06 Osaka University 免疫刺激オリゴヌクレオチドおよびその医薬用途
WO2006108358A1 (en) * 2005-04-13 2006-10-19 Changchun Huapu Biotechnology Co., Ltd. ANTIVIRAL USE OF ARTIFICIAL CpG-CONTAINING SINGLE-STRANDED OLIGODEOXYNUCLEOTIDES IN COMBINATION WITH RIBAVIRIN

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAMSTRUP, S. ET AL.: "Response of porcine peripheral blood mononuclear cells to CpG- containing oligodeoxynucleotides", VET MICROBIOL, vol. 78, no. 4, 2001, pages 353 - 362 *
YAMAMOTO, S. ET AL.: "Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity", J IMMUNOL, vol. 148, no. 12, 1992, pages 4072 - 4076 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11578331B2 (en) 2015-09-09 2023-02-14 Gilead Sciences, Inc. Combination comprising immunostimulatory oligonucleotides
US11583581B2 (en) 2015-09-21 2023-02-21 Gilead Sciences, Inc. Methods of treating a retroviral infection

Also Published As

Publication number Publication date
JP5359883B2 (ja) 2013-12-04
JPWO2009069682A1 (ja) 2011-04-14

Similar Documents

Publication Publication Date Title
IL217332A (en) Preparations containing irna materials, pharmaceutical compositions containing them and their use in the manufacture of drugs to lower the level of respiratory virus protein @ syncial @ rsv @@@ mrna @ of @ rsv @ or @ concentration @ of @ rsv
ATE416183T1 (de) Oligonukleotide mit alternierenden segmenten und deren verwendungen
WO2007112028A3 (en) 2'-fluoronucleoside phosphonates as antiviral agents
RU2014117018A (ru) Аптамер против ngf и его применение
IL140264A0 (en) Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
WO2007020193A3 (en) Antiviral phosphoramidates of 4 ' -substituted pronucleotides
PL366726A1 (en) 4'-substituted nucleosides for the treatment of diseases mediated by the hepatitis c virus
WO2002069903A3 (en) Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
WO2001077091A3 (en) Ns5b hcv polymerase inhibitors
WO2004041201A3 (en) Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
CA2651453C (en) 5'-modified bicyclic nucleic acid analogs
WO2007070598A3 (en) Nucleotide and oligonucleotide prodrugs
TW200621233A (en) HCV NS3-NS4A protease inhibition
TR200302313T4 (tr) Antivirütik pirimidin nükleosid analogları
WO2000061151A3 (en) Oligodeoxynucleotide and its use to induce an immune response
NZ563845A (en) RNAi sequences against the Influenza A segment 1 PB2 gene and uses thereof as anti-viral therapeutic
WO2007127919A3 (en) Compositions and methods for inhibiting expression of a gene from the jc virus
WO2003101394A3 (en) Defensins: use as antiviral agents
PT1175489E (pt) Oligonucleotidos contendo uma sequencia antisense estabilizada por uma estrutura secundaria e composicoes farmaceuticas contendo as mesmas
MXPA04004621A (es) Nucleotidos, preparaciones de los mismos y su utilizacion como inhibidores de polimerasas virales de arn.
WO2009069682A1 (ja) 肝炎の治療剤又は予防剤
EP1928884A4 (en) 5,6-DIMETHYLTHIENO [2,3-DI] PYRIMIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF FOR THE FIGHT AGAINST VIRUSES
WO2009069447A1 (ja) インフルエンザワクチン用のアジュバント及びインフルエンザワクチン
EP1480992A4 (en) TELOMERASEINTERFERENZ
EP1892293A4 (en) TRANSCRIPTION FACTOR DECOY

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08854921

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009543838

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08854921

Country of ref document: EP

Kind code of ref document: A1